EMVision Medical Devices (ASX:EMV) - CEO, Dr Ron Weinberger
CEO, Dr Ron Weinberger
Source: EMVision
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • EMVision Medical Devices (EMV) spikes in early trade after assembling its first commercial portable brain scanner for testing
  • The device is designed to scan the human brain to monitor strokes and diagnose other conditions and is portable
  • After completing previous clinical tests, EMVision says it has assembled the first generation of portable brain-scanning devices for commercialisation
  • The first-gen EMVision device will now undergo several tests as the company builds towards its next stage of clinical studies for the device
  • Shares in EMVision are up 11.79 per cent and trading at $2.94 each at 10:45 am AEST

Meditech company EMVision Medical Devices (EMV) has spiked in early trade after assembling its first commercial portable brain scanner for testing.

The company has been developing an electromagnetic microwave imaging device to scan the human brain to monitor strokes and diagnose other conditions.

Importantly, EMVision’s device is made to be portable, meaning it’s designed for use in hospitals, clinics, and other settings where conventional neuroimaging machines aren’t available.

Today, EMVision said it has successfully fabricated and assembled the alpha units of its first generation of portable brain scanning tech for commercialisation.

CEO Dr Ron Weinberger said this was an important milestone for the company.

“Our product represents a game-changing opportunity provide accessible point-of-care neuroimaging for stroke patients wherever they are,” Mr Weinberger said.

“The value proposition for our scanner is simple — portable, accessible, fast, and affordable.”

He said the company’s tech is designed to tackle the “immense health burden” of strokes, though it has the potential future applications for traumatic brain injuries and other neurological disorders.

“We see an enormous market opportunity ahead in neuroimaging that is poised for disruption,” he said.

Today’s news follows several successful clinical trials completed for the portable brain scanner technology.

The first-gen EMVision device will undergo several tests as the company builds towards its next stage of clinical studies for the device.

Specifically, EMVision said the devices will be tested for functionality, reliability, software and hardware integration, preliminary safety, and more to ensure the device meets international regulatory standards.

Co-chair of the Australian Stroke Alliance Professor Stephen Davis said the research program for the EMV product is successful, the portable brain scanners could be used in standard ambulances and aircraft.

“It is encouraging to see the progress being made because portable scanning that provides high-quality brain imaging would be indispensable, particularly for the one-third of Australians who live in rural and remote communities who might suffer a stroke,” Professor Davis said.

Shares in EMVision were up 11.79 per cent and trading at $2.94 each at 10:45 am AEST. The company has a $211 million market cap.

EMV by the numbers
More From The Market Herald

" Creso Pharma (ASX:CPH) signs potential partnership with Gotro for Sierra pet products

Creso Pharma (ASX:CPH) signs a heads of agreement with leading pet care distributor, Gotro Global, to…
The Market Herald Video

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.